Triple-negative breast cancers (TNBCs), which lack expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), account for approximately 10 to 17% of all breast cancers [1-3] and are associated with relatively poor clinical outcomes. Here, PGR is linked to triple-negative breast carcinoma.